DMAC
DiaMedica Therapeutics Inc.
4.13
-
0.22
5.06%
1 x 4.06
1 x 4.31
bid
ask
1 @ 04:00 PM
4.13+0.00 (0.00%)
Bearish
2
Bullish
9
sentiment
3.98
day range
4.46
1.94
52 week range
4.95
News
...
Insiders See US$9.05m Investment In DiaMedica Therapeutics Jump Last Week | news.google.com • |
DiaMedica Therapeutics Upcoming Conference Participation | businesswire.com • |
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? | zacks.com • |
DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point | seekingalpha.com • |
DiaMedica Therapeutics Announces $11.8 Million Private Placement | businesswire.com • |
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia | businesswire.com • |
Profile
...
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-11 | 2024-09 | -0.16 | N/A | N/A | N/A |
2024-08-07 | 2024-06 | -0.16 | -0.13 | 0.03 | 18.75% |
2024-05-08 | 2024-03 | -0.16 | -0.14 | 0.02 | 12.50% |
2024-05-08 | 2024-03 | -0.16 | N/A | N/A | N/A |
2024-03-19 | 2023-12 | -0.14 | N/A | N/A | N/A |
2024-03-19 | 2023-12 | -0.14 | -0.14 | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-06-21 | Oppenheimer | Upgrade | Perform | Outperform |
2022-07-06 | Oppenheimer | Downgrade | Outperform | Perform |
2022-07-06 | Craig-Hallum | Upgrade | Buy | |
2022-07-06 | Lake Street | Upgrade | Buy | |
2021-06-29 | Roth Capital | Upgrade | Buy | |
2021-04-07 | Oppenheimer | Upgrade | Outperform |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-01-01 | GIUFFRE RANDALL MICHAEL | Director | 411.19K | Stock Award(Grant) |
2023-06-22 | KELLEN SCOTT | Chief Financial Officer | 32.29K | Purchase |
2024-01-01 | KUNTZ RICHARD P | Director | 14.29K | Stock Award(Grant) |
2024-01-01 | PARSONS JAMES T CPA | Director | 59.94K | Stock Award(Grant) |
2023-06-22 | PAULS DIETRICH JOHN | Chief Executive Officer | 68.59K | Purchase |
2024-01-01 | PILNIK RICHARD D | Director | 278.60K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Cooperman, Leon G. | 875.99K | 3.78M | 2.31% |
2023-06-29 | Vanguard Group Inc | 782.99K | 3.38M | 2.06% |
2023-06-29 | Paragon Associates & Paragon Associates Ii Joint Venture | 325.00K | 1.40M | 0.86% |
2023-06-29 | Bleichroeder LP | 294.12K | 1.27M | 0.78% |
2023-06-29 | EAM Investors, LLC | 270.42K | 1.17M | 0.71% |
2023-06-29 | Jacob Asset Management of New York LLC | 198.73K | 858.51K | 0.52% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 506.27K | 2.19M | 1.33% |
2023-06-29 | Vanguard Extended Market Index Fund | 228.62K | 987.64K | 0.60% |
2023-08-30 | Jacob Discovery Fd | 178.73K | 527.25K | 0.47% |
2023-05-30 | Fidelity Extended Market Index Fund | 82.67K | 225.69K | 0.22% |
2023-08-30 | iShares Micro Cap ETF | 53.50K | 157.83K | 0.14% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 42.74K | 116.68K | 0.11% |
Split
...
Split | Date |
---|---|
1 : 20 | 2018-11-15 |
This topic has been deleted. Only users with topic management privileges can see it.
-
This stock could never in a Green Day pass $5! Why?? Because we have too many scare selling folks that would rather make pennies than dollarsβ¦.
-
$DIAMEDICA THERAPEUTICS INC. FOLKS, WHY ARE YOU SCARE SELLING FOR PENNIES!! HOLD HOLD HOLD!! LET YOUR MONEY MAKE MORE MONEY FOR YOU!!!!HOLD HOLD!!!
-
WHY ARE PEOPLE SO SPINELESS AND WEAK TO SELL SHORT RATHER THAN TO HOLD THEIR MONEY LONGER TO MAKE MORE MONEY?? ITS TRULY SAD THAT PEOPLE ARE SELLING SCAREβ¦β¦.
-
FOLKS WHY ARE YOU SELLING SHORT??? LET YOUR MONEY MAKE MORE MONEY FOR YOU!!! HOLD HOLD HOLD AND WE MAKE THE PRICE SKYROCKET!!!!!
-
-
-
FOLKS, DO NOT SALE FOR PENNIES!!! LET YOUR MONEY MAKE MORE MONEY FOR YOU!!!! JIST HOLD HOLD HOLD HOLD!!!! WE WILL SKYROCKET THE PRICE UP!!!!!
-
DiaMedica Therapeutics Upcoming Conference Participation
businesswire.com • -
DiaMedica Therapeutics Announces $11.8 Million Private Placement
businesswire.com • -
DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
investorplace.com • -
DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
investorplace.com • -
DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript
seekingalpha.com •